How Pharma Manufacturers Are Changing Copay Programs To Combat Accumulators and Maximizers
Since the rise of accumulator and maximizer programs, many stakeholders within the pharmacy industry have been looking to tip the scales back towards traditional copay assistance models.
3 Ways Pharmacy Benefit Programs Can Prepare for Biosimilar Drugs
By understanding your contract, communicating with your PBM, and working with a partner to craft your pharmacy strategy, you’ll be well prepared for the rise of biosimilar drugs.
The Accumulator Adjustment Ruling of 2023 – What’s Next for Brands
On May 17, 2022, the U.S. District Court for DC ruled against the “accumulator adjustment rule.” What impact will this have on pharma?
6 Takeaways from the Asembia 2022 Specialty Pharmacy Summit
6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?
Asembia 2021: Four Key Takeaways
Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.
The Impact of COVID-19 on Brand Prescribing and Claims
Read Truveris’ data report on the impact of COVID-19 on pharma, specifically prescribing and claims numbers for branded drugs.
Podcast - The Future of the PBM Landscape
What is the future of the PBM landscape? Listen to Truveris CEO, Nanette Oddo, opine on the shifts she’s seeing in the pharmacy ecosystem.
Truveris Appoints Nanette Oddo President and Chief Executive Officer
Truveris announced today that Nanette Oddo, formerly Truveris’ Chief Strategy Officer, has been named President and Chief Executive Officer.
Industry Update: The Impact of State Legislation on Copay Accumulator Programs
Several states have passed legislation that prohibits the use of copay accumulator adjustment programs. How does this affect your organization?